late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored LAMTOR3P2 profile across patient tissues and cancer cell-line models. LAMTOR3P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LAMTOR3P2 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, LAMTOR3P2 RNA expression shows 12,254 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, LUAD, and UVM as cancer lineages where LAMTOR3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAMTOR3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAMTOR3P2 survival associations across molecular data types. LAMTOR3P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAMTOR3P2 RNA expression–survival associations across cancer types. High LAMTOR3P2 expression shows unfavorable associations in COAD, CESC, KIRC and GBM, but favorable associations in BLCA and LGG. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LAMTOR3P2 RNA expression.
This table summarizes LAMTOR3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LAMTOR3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAMTOR3P2 shows lower tumor expression in READ and STAD and higher tumor expression in LUAD, LUSC and THCA. The LUAD box plot shows higher LAMTOR3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.374, t-test p = .002).
This table shows molecular features associated with LAMTOR3P2 in patient tissues and cancer cell lines. In patient samples, LAMTOR3P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
